<DOC>
	<DOCNO>NCT02285231</DOCNO>
	<brief_summary>In double-blind , placebo-controlled study , subject prediabetes type 2 diabetes randomly assign placebo control group test ( Arginyl-fructose : AF ) group . We determine fast serum level glucose , hemoglobin A1c ( HbA1c ) , insulin , free fatty acid ( FFAs ) , measure 2-h oral glucose tolerance test ( OGTTs ) baseline 6-week intervention .</brief_summary>
	<brief_title>Anti-hyperglycemic Effect Short-term Arginyl-fructose Supplementation Subjects With Pre-diabetes Newly Diagnosed Type 2 Diabetes : Randomized , Double-blinded , Placebo-controlled Trial .</brief_title>
	<detailed_description />
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>All subject prediabetes ( IFG IGT ) newly diagnose type 2 DM ( T2DM ) take medicine . IFG define fast glucose 100 125 mg/dL IGT define 2h OGTTs glucose level 140199 mg/dL . Newly diagnose type 2 diabetes define fast glucose ≥126 mg/dL 2h OGTTs level ≥ 200 mg/dL . Exclusion criterion include 1 ) glucose lower medication insulin injection ; 2 ) abnormal liver renal function ; 3 ) chronic stomach intestines disease ; 4 ) chronic alcoholism ; 5 ) pregnancy intend become pregnant time study . 6 ) complication ; 7 ) occupation could dangerous hypoglycemia occur .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Anti-hyperglycemic effect</keyword>
</DOC>